A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study ofMaintenance Olaparib Monotherapy in Patients with gBRCA Mutated MetastaticPancreatic Cancer whose Disease Has Not Progressed on First Line Platinum BasedChemotherapy
A study for patients with pancreatic cancer using study drug Olaparib
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAO2705
U.S. Govt. ID: NCT02184195
Contact: Paul Oberstein: 646-317-6085 / p02178@cumc.columbia.edu
Additional Study Information: This research study is being conducted to see if a new treatment using a study drug called Olaparib given after platinum based chemotherapy treatments can reduce the risk of pancreatic cancer from growing back. Participants will receive either Olaparib or placebo (no contains active medication) and will stay on the research study for as long as they are not getting worse.
This study is closed
Investigator
Paul Oberstein, MD
Do You Qualify?
Do you have a diagnosis of pancreatic adenocarcinoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Paul Oberstein
p02178@cumc.columbia.edu
646-317-6085